| Price Range 12mo avg: | $940K – $6.3M |
|---|---|
| $/sf 12mo avg: | $376 |
| CAP Rate 12mo avg: | 6.87% |
| NOI average: | $193,167 |
| Lease Terms: | 15yrs NN |
| Building Size avg: | 8,000 SF |
| Lot Size avg: | 0.75+/- acres |
DaVita Kidney Care is a division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of dialysis services in the United States, DaVita Kidney Care treats patients with chronic kidney failure and end stage renal disease. DaVita Kidney Care strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health management services. As of September 30, 2015, DaVita Kidney Care operated or provided administrative services at 2,225 outpatient dialysis centers located in the United States serving approximately 177,000 patients. The company also operated 104 outpatient dialysis centers located in 10 countries outside the United States. DaVita Kidney Care supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu.
DaVita—which is Italian for “giving life”—has more than 50,000 teammates (employees) around the nation working to provide superior patient care and exemplify the company’s Core Values
| S&P Credit Rating: | BB- |
|---|---|
| Moody’s Credit Rating: | Ba3 |
| Annual Revenue 2014: | $12.8B |
| Annual Revenue 2013: | $11.8B |
| Revenue Growth: | ↑ 8.13% from 2013 |
| Net Income | $723M |
| Units (Dec. 2014) | 2,179 |
| Average Units Volume: | $331856K |
Yahoo! Finance: DVA News Latest Financial News for DVA
-
If You Had Bought DaVita (NYSE:DVA) Stock Three Years Ago, You Could Pocket A 70% Gain Today
on April 14, 2021 at 6:41 am
It hasn't been the best quarter for DaVita Inc. ( NYSE:DVA ) shareholders, since the share price has fallen 11% in that... […]
-
Blue Cross and Blue Shield of Minnesota Launches Program with DaVita's VillageHealth to Improve Care for Members with Kidney Disease
on April 12, 2021 at 2:00 pm
Blue Cross and Blue Shield of Minnesota (Blue Cross) today announced the launch of an innovative new program with VillageHealth − a DaVita integrated kidney care program − that addresses the holistic health needs of certain eligible members with chronic kidney disease (CKD) or end stage kidney disease (ESKD). […]
-
DaVita (DVA) Partners With Fresenius, Boost Home Dialysis Care
on March 29, 2021 at 1:00 pm
DaVita's (DVA) recent collaboration will help patients benefit from the portability, dependability and flexibility of NxStage home machines, designed to be easy to use. […]
-
DaVita Shares Strategy for Achieving a Diverse Community Where Everyone Belongs
on March 29, 2021 at 10:05 am
DaVita today published its inaugural Diversity & Belonging (D&B) report, which discloses its diversity metrics and roadmap for delivering its vision of cultivating "a diverse Village where everyone belongs." […]
-
BofA Downgrades DaVita On Low Exposure to Volume Rebound
on March 26, 2021 at 6:06 pm
Since dialysis is a stable business, Davita Inc (NYSE: DVA) remained resilient during the pandemic. However, now with acceleration in volumes is poised to begin, the company “is not as levered to the expected utilization rebound as peers,” according to BofA Securities. The DaVita Analyst: Kevin Fischbeck downgraded the rating for DaVita from Neutral to Underperform, while reducing the price target from $127 to $118. The DaVita Thesis: Hospitals are best positioned to benefit from the expected above average growth in procedures due to pent-up demand during the pandemic, Fischbeck said in the downgrade note. “Health care utilization is likely to recover in the back half of 2021, with continued vaccinations and a return to elective procedures,” the analyst added. Fischbeck noted, however, that DaVita is likely to underperform peers, with dialysis seeing “headwinds from high mortality.” He elaborated in the note, “DVA guided to 2021 operating income (OI) slightly below expectations given same store volumes are expected to decline 1-2% y/y due to the higher mortality of dialysis patients during the pandemic.” DVA Price Action: Shares of DaVita had declined by 2.43% to $108.17 at the time of publication Friday afternoon. (Photo by JESHOOTS.COM on Unsplash) Latest Ratings for DVA DateFirmActionFromTo Mar 2021B of A SecuritiesDowngradesNeutralUnderperform Jan 2021B of A SecuritiesDowngradesBuyNeutral May 2020SunTrust Robinson HumphreyMaintainsHold View More Analyst Ratings for DVA View the Latest Analyst Ratings See more from BenzingaClick here for options trades from BenzingaWhy This Lumentum Analyst Is Bullish After Coherent M&A Deal Falls ApartIntel's 'Strategic Faux Pas' Could Be AMD's Gain Says Northland Capital Analyst© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. […]
NYSE: DVA
